Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO. - Concepedia

Concepedia

Publication | Closed Access

Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.

13

Citations

0

References

2008

Year

Guelten Oskay-Oezcelik, Dominique Koensgen, Hans-Joachim Hindenburg, Peter Klare, Barbara Schmalfeldt, W. Lichtenegger, Radoslav Chekerov, Salah‐Eddin Al‐Batran, Ulf P. Neumann, Jalid Sehouli

Abstract

Biweekly PLD is an effective second-line treatment for patients with relapsed ovarian cancer. Toxicity incidence with this treatment schedule does not appear to be associated with the number of previous chemotherapies. Our data supports the need for a randomized study comparing biweekly with conventional monthly administration of 40 mg/m2 or 50 mg/m2 PLD to determine the best therapeutic index for PLD.